Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY 24 FE vs AUROVELA FE 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination oral contraceptive containing ethinyl estradiol and norethindrone; inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. Inhibits ovulation by suppressing gonadotropin release (FSH, LH). Increases viscosity of cervical mucus, reducing sperm penetration. Alters endometrial lining to reduce implantation likelihood.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years who have achieved menarche and no known contraindications)
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years old who have reached menarche and desire contraception,Treatment of heavy menstrual bleeding in women without organic pathology
One tablet orally once daily for 24 weeks. Each tablet contains norethindrone 0.8 mg and ethinyl estradiol 0.02 mg. After 24 weeks, take one inactive (ferrous fumarate) tablet daily for 4 weeks. Total cycle: 28 tablets.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by one iron tablet (75 mg ferrous fumarate) orally once daily for 7 days.
Ethinyl estradiol has a terminal half-life of approximately 13-27 hours (mean 18.5 hours). Norethindrone has a terminal half-life of approximately 8-12 hours. The half-life supports once-daily dosing.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours (with interindividual variability).
Ethinyl estradiol is primarily metabolized by CYP3A4; undergoes first-pass metabolism in the liver and intestinal mucosa. Norethindrone is metabolized via reduction, hydroxylation, and conjugation, primarily by CYP3A4.
No dosage adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and hyperkalemia from the progestin component.
No dosage adjustment required for mild to moderate renal impairment. Contraindicated in patients with markedly impaired renal function due to potential fluid retention and estrogen-related adverse effects.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use. Risk increases with age (>35 years) and with heavy smoking (≥15 cigarettes/day). Women >35 years who smoke should not use this product.
Hailey 24 FE contains ethinyl estradiol and norethindrone. Contraindicated in pregnancy. First trimester: No increased risk of birth defects from inadvertent use based on population data. Second and third trimesters: Known risks include genital abnormalities in female fetuses from androgenic progestins, although norethindrone has low androgenicity. Avoid use during pregnancy.
AUROVELA FE 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is associated with a slightly increased risk of congenital anomalies, including cardiovascular and limb defects. Second and third trimester exposure may cause fetal harm, including feminization of male fetuses and genitourinary abnormalities. No known risk of miscarriage.
HAILEY 24 FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It provides 24 active tablets with 0.8 mg norethindrone and 0.025 mg ethinyl estradiol, followed by 4 ferrous fumarate tablets (75 mg) to maintain adherence. Monitor for breakthrough bleeding, which is common in the first 3 months. Counsel patients that taking at the same time daily is critical for efficacy. Missed pill management: if one active pill is missed, take as soon as remembered; if two or more are missed, take the most recent missed and use backup contraception for 7 days.
AUROVELA FE 1/20 contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg with ferrous fumarate (iron) in the placebo pills. It is a monophasic oral contraceptive with low estrogen dose; consider for patients needing iron supplementation or those with heavy menstrual bleeding. The ferrous fumarate may cause gastrointestinal upset or dark stools. Breakthrough bleeding is more common with 20 mcg EE pills. Advise consistent dosing at the same time daily to maintain efficacy. Contraindicated in patients with migraine with aura, hypertension (>160/100), or history of thromboembolism. Monitor for signs of DVT/VTE, especially in smokers over 35.
No interactions on record
No interactions on record
HAILEY 24 FE and AUROVELA FE 1/20 are distinct pharmacological agents. HAILEY 24 FE belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyTreatment of moderate acne vulgaris (in females ≥15 years who have achieved menarche and no known contraindications). AUROVELA FE 1/20 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyTreatment of moderate acne vulgaris in females ≥15 years old who have reached menarche and desire contraceptionTreatment of heavy menstrual bleeding in women without organic pathology. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. HAILEY 24 FE carries a safety status of Category C, whereas AUROVELA FE 1/20 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Ethinyl estradiol undergoes CYP3A4 metabolism and first-pass conjugation; norethindrone acetate is deacetylated to norethindrone, primarily metabolized by CYP3A4 and reduction pathways.
Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone is excreted in urine (30-50%) and feces (20-30%) as metabolites.
Renal: ~50-60% as metabolites; fecal: ~40-50% as metabolites; biliary excretion contributes to fecal elimination.
Ethinyl estradiol: 97-98% bound to albumin and corticoid-binding globulin (CBG). Norethindrone: 80-90% bound to sex hormone-binding globulin (SHBG) and albumin.
Norethindrone: ~61% bound to albumin and SHBG; ethinyl estradiol: ~97% bound to albumin.
Ethinyl estradiol: Vd 2.0-4.5 L/kg, indicating extensive tissue distribution. Norethindrone: Vd 2.0-3.0 L/kg, also widely distributed.
Norethindrone: ~2.7 L/kg; ethinyl estradiol: ~1.9 L/kg; distributes into breast milk.
Ethinyl estradiol: 38-48% oral bioavailability due to first-pass metabolism. Norethindrone: 64-70% oral bioavailability. Both are subject to hepatic first-pass metabolism.
Oral: Norethindrone ~64%; ethinyl estradiol ~45% (first-pass metabolism).
Contraindicated in Child-Pugh Class B or C (moderate to severe hepatic impairment). For Child-Pugh Class A (mild impairment), use with caution; consider alternative contraceptive methods due to potential altered hormone metabolism.
Contraindicated in patients with acute or chronic hepatic dysfunction, including Child-Pugh A, B, or C cirrhosis, due to impaired steroid metabolism.
Postmenarchal adolescents: Same dosing as adults (one tablet daily). Safety and efficacy have been established for females of reproductive age. Not indicated for premenarchal girls.
Post-menarche: same as adult dosing (one tablet daily for 21 days, then iron tablet for 7 days). Not indicated before menarche.
Not indicated for postmenopausal women. No safety data available for females over 65 years. Contraindicated in women with known or suspected pregnancy or history of thromboembolic disorders.
Not indicated for use after menopause. No specific dose adjustment; use lowest effective dose if considered for other indications, but generally avoid due to increased risk of thromboembolism and cardiovascular events.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders (DVT, PE, stroke, MI), especially in smokers >35 years. Risk of hepatic neoplasia. Elevated blood pressure. Gallbladder disease. Carbohydrate and lipid effects. Headache. Uterine bleeding irregularities. Discontinue if jaundice, vision loss, or thromboembolic symptoms occur.
Thrombophlebitis or thromboembolic disorders. History of DVT/PE. Cerebrovascular or coronary artery disease. Known or suspected breast cancer. Estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Known or suspected pregnancy. Active liver disease or hepatic adenoma. Hypersensitivity to components. Smokers >35 years.
Avoid grapefruit and grapefruit juice as they may increase ethinyl estradiol levels. No other significant food interactions.
No significant food interactions. Avoid grapefruit juice as it may increase estrogen levels. Ferrous fumarate absorption is enhanced by vitamin C (e.g., citrus) and decreased by calcium supplements or dairy; take iron tablets separately from high-calcium meals if concerned. Alcohol is not contraindicated but may increase risk of liver toxicity in high doses; limit consumption.
Small amounts of ethinyl estradiol and norethindrone excreted in breast milk. M/P ratio not well defined. May reduce milk production and quality, especially with higher doses. Use not recommended during lactation; alternative contraception advised.
Small amounts of contraceptive steroids and/or metabolites are excreted in breast milk. Milk-to-plasma (M/P) ratio: not established. Use may reduce milk production and composition; if possible, use alternative contraception. AAP considers it compatible with breastfeeding but caution advised.
Contraindicated in pregnancy; no dose adjustments applicable. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) would not be relevant as the drug is not used.
No dose adjustment is indicated as the drug is contraindicated in pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered hepatic metabolism) may require dose adjustment if inadvertently used, but no established recommendations.
Take one tablet daily at the same time each day, with or without food.,The first 24 tablets are hormone-containing; the last 4 are iron tablets that do not prevent pregnancy.,If you have vomiting or severe diarrhea within 4 hours of taking a pill, treat it as a missed pill.,Common side effects include nausea, headache, and breakthrough bleeding, which often improve after 2-3 months.,Report serious symptoms like severe leg pain, chest pain, or sudden vision changes immediately.,Use backup contraception (e.g., condoms) if you miss 2 or more active pills.
Take one tablet daily at the same time, with or without food.,If you miss a pill, refer to the package leaflet or consult your provider; for missing active pills, take the missed pill as soon as remembered and use backup contraception for 7 days.,The last 7 pills (brown) are iron tablets and should be taken even if you don't have a period; they do not prevent pregnancy.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially during the first few cycles.,This pill does not protect against HIV or other sexually transmitted infections; use condoms for STD prevention.,Avoid smoking, especially if over 35, due to increased risk of blood clots.,Ferrous fumarate may cause dark or greenish stools; this is harmless.,Contact your doctor immediately if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes.